Brain tumor treatment or prevention of recurrence with low intensity and variable frequency magnetic stimulation
AssigneeActipulse Neuroscience Inc.
InventorsGabriel Villafuerte, Adrien Châtillon, Irina Vazquez Villaseñor
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, in part, methods of treatment and prevention of recurrence for brain tumors, e.g., without limitation, GBM comprising applying repetitive transcranial magnetic stimulation (rTMS) therapy to a patient in need thereof. The present disclosure also provides devices that generate a low intensity magnetic field and variable frequencies.
Claims33
A repetitive transcranial magnetic stimulation (rTMS) method for treating or preventing a brain cancer comprising repetitively applying a magnetic pulse with one or more coils configured to emit a magnetic field to the scalp of a patient in need thereof thereby affecting cancer cells in the brain of the patient, wherein the magnetic pulse is applied:
- repetitively over the patient's brain;
- and
- at a frequency of about 10 Hz to about 500,000 Hz and an intensity of about 0.0005 Tesla to about 0.1 Tesla.
A repetitive transcranial magnetic stimulation (rTMS) method for slowing or preventing the recurrence of brain cancer comprising repetitively applying a magnetic pulse with one or more coils configured to emit a magnetic field to the scalp of a patient in need thereof thereby affecting cancer cells in the brain of the patient, wherein the magnetic pulse is applied:
- repetitively over the patient's brain;
- and
- at a frequency of about 10 Hz to about 500,000 Hz and an intensity of about 0.0005 Tesla to about 0.1 Tesla.
The method of any one of the previous claims, wherein the magnetic pulse is applied at an intensity of about 0.001 Tesla to 0.1 Tesla.
The method of any one of the previous claims, wherein the magnetic pulse applied at an intensity of about 0.01 Tesla.
The method of any one of the previous claims, wherein the brain cancer is a brain tumor and/or metastasis.
The method of any one of the previous claims, wherein the method further comprises surgical resection, radiotherapy, and/or administration of chemotherapy.
The method of any one of the previous claims, wherein the patient has undergone or is undergoing surgical resection, radiotherapy, and/or administration chemotherapy.
The method of any one of the previous claims, wherein the rTMS treatment is self-applied.
The method of any one of the previous claims, wherein the magnetic pulse is applied using a device, wherein the device is suitable for conducting electric current through the one or more coils to emit the magnetic field.
The method of any one of the previous claims, where in the patient is afflicted with glioblastoma multiforme (GBM).
The method of any one of the previous claims, wherein the patient is afflicted with one or more symptoms selected from intracranial hypertension, headaches, seizures, sensory disturbances, neurocognitive symptoms, and motor symptoms.
The method of any one of the preceding claims, wherein the patient presents as having the diagnosis of GBM according to The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System.
The method of any one of the preceding claims, wherein the method stimulates tumor cells within about 1 cm to about 2 cm from the skull, within about 1 cm to about 3 cm from the skull, within about 1 cm to about 4 cm from the skull, or within about 1 cm to about 5 cm from the skull.
The method of any one of the preceding claims, wherein the magnetic pulse is applied repetitively over the patient's skull as a function of a location of a tumor.
The method of any one of the preceding claims, further comprising identifying a location of a tumor prior to administering the rTMS and/or after applying the rTMS, optionally using one or more of magnetic resonance imaging (MRI), computed tomography (CT) scan, and X-ray.
The method of any one of the preceding claims, wherein the method reduces, impairs, and/or decreases tumor growth, migration, invasiveness, and/or spread throughout the patient's brain.
The method of any one of the preceding claims, wherein the method prevents or delays the recurrence of GBM.
The method of any one of the preceding claims, wherein the treatment improves symptoms of the patient, optionally symptoms of GBM.
The method of any one of the preceding claims, wherein the treatment curtails or prevents exacerbation of GBM.
The method of any one of the preceding claims, wherein the treatment is used in tandem with one or more additional therapeutic agents.
The method of any one of the preceding claims, wherein the rTMS treatment obviates the need for treatment with one or more additional therapeutic agents and/or additional therapeutic modalities;
- and/or wherein the rTMS treatment allows for reduction of the dosage or frequency of administration of one or more additional therapeutic agents and/or additional therapeutic modalities.
The method of any one of the preceding claims, wherein the rTMS treatment is substantially free of adverse effects, optionally selected from epileptic seizures, nausea, headache, vagal response, musculoskeletal pain, scalp petechial rash, scalp pain, edema, or bruising.
Dependencies are inferred from the claim text.